ArticleEndocrine-related cancer2019
177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition.
Article in Endocrine-related cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- Emergency Appendectomy during the Early Phase afterSurgical case reports · 2026Article
- Preclinical synergistic effects when combining a radiolabelled HER2-targeting single domain antibody with PARP inhibitor Olaparib.Journal of translational medicine · 2025Article
- Radiosensitization of NET cells by HSP90 inhibitor ganetespib is mediated through pleiotropic stress responses.EJNMMI research · 2025Article
- Review
- Evaluation of Oxidative Stress and Endothelial Dysfunction in COVID-19 Patients.Medicina (Kaunas, Lithuania) · 2024Article
- Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- HSP90 expression is associated with outcome in pulmonary carcinoid tumor patients.Translational lung cancer research · 2023Article
- Integrated multi-omics analysis reveals the molecular interplay between circadian clocks and cancer pathogenesis.Scientific reports · 2023Article
- Review
- Peptide Receptor Radionuclide Therapy with [Cancers · 2022Review
- EANM position paper on the role of radiobiology in nuclear medicine.European journal of nuclear medicine and molecular imaging · 2021Article
- Role of Heat Shock Proteins (HSP70 and HSP90) in Viral Infection.International journal of molecular sciences · 2021Review
- Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy.Current oncology reports · 2021Review
- Combination Strategies to Improve Targeted Radionuclide Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Article
- The radiosensitizer Onalespib increases complete remission inEuropean journal of nuclear medicine and molecular imaging · 2020Article
- Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward.Current topics in medicinal chemistry · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
177Lu-octreotate is an FDA-approved radionuclide therapy for patients with gastroenteropancreatic neuroendocrine tumours (NETs) expressing somatostatin receptors. The 177Lu-octreotate therapy has shown promising results in clinical trials by prolonging progression-free survival, but complete responses are still uncommon. The aim of this study was to improve the 177Lu-octreotate therapy by means of combination therapy. To identify radiosensitising inhibitors, two cell lines, GOT1 and P-STS, derived from small intestinal neuroendocrine tumours (SINETs), were screened with 1,224 inhibitors alone or in combination with external radiation. The screening revealed that inhibitors of Hsp90 can potentiate the tumour cell-killing effect of radiation in a synergistic fashion (GOT1; false discovery rate <3.2×10-11). The potential for Hsp90 inhibitor ganetespib to enhance the anti-tumour effect of 177Lu-octreotate in an in vivo setting was studied in the somatostatin receptor-expressing GOT1 xenograft model. The combination led to a larger decrease in tumour volume relative to monotherapies and the tumour-reducing effect was shown to be synergistic. Using patient-derived tumour cells from eight metastatic SINETs, we could show that ganetespib enhanced the effect of 177Lu-octreotate therapy for all investigated patient tumours. Levels of Hsp90 protein expression were evaluated in 767 SINETs from 379 patients. We found that Hsp90 expression was upregulated in tumour cells relative to tumour stroma in the vast majority of SINETs. We conclude that Hsp90 inhibitors enhance the tumour-killing effect of 177Lu-octreotate therapy synergistically in SINET tumour models and suggest that this potentially promising combination should be further evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.